Clinical Trial News and Research

RSS

ChromaDex reports 42% increase in Q2 2014 net sales

ChromaDex Corp., an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended June 28, 2014.

12 Aug 2014

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries.

12 Aug 2014

GenoSpace completes financing deal with Thomson Reuters

GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, today announced that it completed a financing deal with Thomson Reuters, the world leader in providing intelligent information for businesses and professionals.

12 Aug 2014

Omeros reports net loss of $18 million for second quarter 2014

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014.

12 Aug 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share.

12 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

$Sacral magnetic stimulation effective in refractory stress incontinence$

Sacral magnetic stimulation effective in refractory stress incontinence

Sacral magnetic stimulation may be an effective treatment for stress urinary incontinence in women whose symptoms are refractory to standard therapies, a clinical trial suggests.

11 Aug 2014

Health law funds new search for health care improvements

News outlets report on aspects of the health law designed to foster and test innovation in the nation's health care delivery system.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.

11 Aug 2014

Patient with mechanical heart pump receives new gene therapy for heart failure

For the first time in the world, a patient with a mechanical heart pump has received a new gene therapy for heart failure at Harefield Hospital, London.

11 Aug 2014

Retina's Alpha IMS microchip receives NUB innovation status from Germany statutory health insurance

Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that the Company's Alpha IMS microchip was granted NUB innovation status and will now be reimbursed by Germany's statutory health insurance system.

11 Aug 2014

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma.

8 Aug 2014

Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

New research partly led by UC San Francisco-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated, and that this information, in turn, could lead to more appropriate treatments.

8 Aug 2014

Neurons derived from human iPSC and grafted into rats after spinal cord injury produce cells

Building upon previous research, scientists at the University of California, San Diego School of Medicine and Veteran's Affairs San Diego Healthcare System report that neurons derived from human induced pluripotent stem cells (iPSC) and grafted into rats after a spinal cord injury produced cells with tens of thousands of axons extending virtually the entire length of the animals' central nervous system.

8 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

Clinical trial provides women with more accurate way to detect cervical cancer

Jersey Shore University Medical Center is conducting a clinical trial that provides women with a more accurate way to detect cervical cancer.

8 Aug 2014

Longer looks: Kentucky is health law poster child; how to negotiate a lower medical bill; the Ebola outbreak up close

About a year ago, on Aug. 22, a team of inspectors from the Centers for Medicare and Medicaid Services (CMS) unit of the U.S. Department of Health and Human Services arrived in Frankfort, Ky., to see if the people working out of a nondescript warehouse there were going to be able to pull off the launch of Kentucky's Obamacare health-insurance exchange.

8 Aug 2014

Tumor genetic analysis reveals new approach of classifying cancers

Researchers with The Cancer Genome Atlas (TCGA) Research Network have completed the largest, most diverse tumor genetic analysis ever conducted, revealing a new approach to classifying cancers.

8 Aug 2014

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

Clinical Trial News and Research

ChromaDex reports 42% increase in Q2 2014 net sales

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

GenoSpace completes financing deal with Thomson Reuters

Omeros reports net loss of $18 million for second quarter 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

Sacral magnetic stimulation effective in refractory stress incontinence

Health law funds new search for health care improvements

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Patient with mechanical heart pump receives new gene therapy for heart failure

Retina's Alpha IMS microchip receives NUB innovation status from Germany statutory health insurance

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

Neurons derived from human iPSC and grafted into rats after spinal cord injury produce cells

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

Clinical trial provides women with more accurate way to detect cervical cancer

Longer looks: Kentucky is health law poster child; how to negotiate a lower medical bill; the Ebola outbreak up close

Tumor genetic analysis reveals new approach of classifying cancers

Idera collaborates with TMA to advance new potential treatment approach for myositis

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery